186 related articles for article (PubMed ID: 37283174)
1. [Indications for CAR-T cell therapy and management of the complications: an update].
Di Lorenzo S; Errichiello S; Cerne D; Venturini M; Visintini C
Assist Inferm Ric; 2022; 41(4):195-211. PubMed ID: 37283174
[TBL] [Abstract][Full Text] [Related]
2. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
3. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.
Fortin Ensign SP; Gaulin C; Hrachova M; Ruff M; Harahsheh E; Vicenti K; Castro J; Munoz J; Rosenthal A; Mrugala MM
Curr Treat Options Oncol; 2022 Dec; 23(12):1845-1860. PubMed ID: 36525238
[TBL] [Abstract][Full Text] [Related]
5. Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
Epperly R; Giordani VM; Mikkilineni L; Shah NN
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1169-1188. PubMed ID: 37349152
[TBL] [Abstract][Full Text] [Related]
6. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
7. Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review.
Amicucci M; Simioli V; De Cecco V; Orlando L; Ciaralli I; Buccino A; Guidi B; Locatelli G; Palmieri C; Piazzalunga M; Proietti R; Pucci A; Botti S
Semin Oncol Nurs; 2023 Oct; 39(5):151478. PubMed ID: 37544775
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
Karam A; Mjaess G; Martinez Chanza N; Aoun F; Bou Kheir G; Younes H; Kazzi H; Albisinni S; Roumeguère T
Cancer Invest; 2022 Nov; 40(10):923-937. PubMed ID: 36102932
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS; Tummala S; Kebriaei P; Wierda W; Gutierrez C; Locke FL; Komanduri KV; Lin Y; Jain N; Daver N; Westin J; Gulbis AM; Loghin ME; de Groot JF; Adkins S; Davis SE; Rezvani K; Hwu P; Shpall EJ
Nat Rev Clin Oncol; 2018 Jan; 15(1):47-62. PubMed ID: 28925994
[TBL] [Abstract][Full Text] [Related]
10. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
11. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Rafiq S; Hackett CS; Brentjens RJ
Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
13. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.
Martino M; Macheda S; Aguglia U; Arcudi L; Pucci G; Martino B; Altomonte M; Rossetti AM; Cusumano G; Russo L; Imbalzano L; Stelitano C; Alati C; Germano' J; Labate D; Amalfi V; Florenzano MT; Morabito A; Borzumati V; Dattola V; Gattuso C; Moschella A; Quattrone D; Curmaci F; Franzutti C; Scappatura G; Rao CM; Loddo V; Pontari A; Pellicano' M; Surace R; Sanguedolce C; Naso V; Ferreri A; Irrera G; Console G; Moscato T; Loteta B; Canale FA; Trimarchi A; Monteleone R; Al Sayyad S; Cirrone F; Bruno B
Expert Opin Biol Ther; 2022 Mar; 22(3):407-421. PubMed ID: 34463175
[TBL] [Abstract][Full Text] [Related]
14. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
15. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
19. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
20. Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Choi G; Shin G; Bae S
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
